Research & Development Market Research Reports & Industry Analysis
Bringing R&D costs and times down, therefore, means there are many opportunities to improve efficiencies, advance technological innovation, and economize and optimize. The pharmaceutical R&D category tracks both drug pipeline reports, competitive R&D strategies, and markets important and ancillary to the research efforts themselves, including activities in the biotech and sector that impinge upon the process.
Research & Development Industry Research & Market Reports
-
Hepatitis C Treatment
... at a CAGR of 10.7% over the analysis period 2024-2030. HCV Protease Inhibitors, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$25.3 Billion by the end ... Read More
-
Soft Tissue Allografts
... at a CAGR of 4.9% over the analysis period 2024-2030. Orthopedic Application, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.9 Billion by the end of ... Read More
-
Human Liver Models
... at a CAGR of 9.3% over the analysis period 2024-2030. Liver Organoids, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$250.6 Million by the end of ... Read More
-
Biotech Business February 2025
... on biotechnology products and companies. It reports which universities offer licensing of biotechnology research, which companies have entered licensing agreements, as well as the financial health of biotechnology companies and their expected growth or decline. Read More
-
Bone Morphogenetic Proteins
... at a CAGR of 2.4% over the analysis period 2024-2030. Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2), one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$484.6 Million ... Read More
-
Protein Binding Assays
... at a CAGR of 9.4% over the analysis period 2024-2030. Equilibrium Dialysis Technology, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$342.2 Million by the end ... Read More
-
Protein Fractionation
... CAGR of 5.4% over the analysis period 2024-2030. Immunoglobulins, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$24.4 Billion by the end of the analysis period. ... Read More
-
Rat Model
... CAGR of 7.1% over the analysis period 2024-2030. Inbred Rat Model, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$901.6 Million by the end of the ... Read More
-
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
... Billion by 2030, growing at a CAGR of 10.8% over the analysis period 2024-2030. Medication Treatment, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$5.5 Billion ... Read More
-
Healthcare Contract Management Software
... 2030, growing at a CAGR of 19.3% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 20.1% CAGR and reach US$7.1 Billion by the ... Read More
-
Quantum Computing in Healthcare
... 2030, growing at a CAGR of 36.9% over the analysis period 2024-2030. Quantum Computing Services, one of the segments analyzed in the report, is expected to record a 40.1% CAGR and reach US$452.4 Million by ... Read More
-
Human Embryonic Stem Cell (hESC) Research
... reach US$1.4 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Regenerative Medicine Application, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and ... Read More
-
Cancer Therapies
... CAGR of 10.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$112.8 Billion by the end of the analysis period. ... Read More
-
Stromal Vascular Fraction
... at a CAGR of 4.5% over the analysis period 2024-2030. Isolation Products, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$99.5 Million by the end of ... Read More
-
Marine Biotechnology
... CAGR of 8.4% over the analysis period 2024-2030. Biomaterials, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$6.5 Billion by the end of the analysis period. ... Read More
-
Healthcare Contract Development and Manufacturing Organization
... reach US$547.1 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Contract Manufacturing, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach ... Read More
-
RNA Interference (RNAi)
... at a CAGR of 10.0% over the analysis period 2024-2030. Drug Discovery & Development Application, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$118.1 Billion by ... Read More
-
Humanized Mouse and Rat Model
... Million by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Humanized Rat Models, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$13.6 ... Read More
-
Beta Interferon
... CAGR of 3.0% over the analysis period 2024-2030. The U.S. Market is Estimated at US$968.9 Million While China is Forecast to Grow at 4.5% CAGR The Beta Interferon market in the U.S. is estimated at ... Read More
-
Albumin
... 3.8% over the analysis period 2024-2030. Human Serum Albumin, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$902.4 Million by the end of the analysis period. ... Read More
-
Biotechnology
... 8.5% over the analysis period 2024-2030. DNA Sequencing Technology, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$33.5 Billion by the end of the analysis period. ... Read More
-
Synthetic Biology
... CAGR of 27.9% over the analysis period 2024-2030. Oligonucleotides & Synthetic DNA Tool, one of the segments analyzed in the report, is expected to record a 29.1% CAGR and reach US$39.5 Billion by the end ... Read More
-
Immune Checkpoint Inhibitors
... at a CAGR of 16.5% over the analysis period 2024-2030. PD-1, one of the segments analyzed in the report, is expected to record a 16.2% CAGR and reach US$109.0 Billion by the end of the ... Read More
-
Neuroscience
... 3.9% over the analysis period 2024-2030. Neuroscience Instruments, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$29.9 Billion by the end of the analysis period. Growth ... Read More
-
PEGylated Proteins
... CAGR of 9.1% over the analysis period 2024-2030. PEGylated Proteins Consumables, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$1.3 Billion by the end of the ... Read More
Research Assistance
